• Accueil
  • Résultats de la recherche
  • Endothelin-1 activation of the endothelin B receptor modulates pulmonary endothelial CX3CL1 and contributes to pulmonary angiogenesis in experimental hepatopulmonary syndrome.

Endothelin-1 activation of the endothelin B receptor modulates pulmonary endothelial CX3CL1 and contributes to pulmonary angiogenesis in experimental hepatopulmonary syndrome.

The American journal of pathology (2014-04-16)
Junlan Zhang, Wenli Yang, Bingqian Hu, Wei Wu, Michael B Fallon
RÉSUMÉ

Hepatic production and release of endothelin-1 (ET-1) binding to endothelin B (ETB) receptors, overexpressed in the lung microvasculature, is associated with accumulation of pro-angiogenic monocytes and vascular remodeling in experimental hepatopulmonary syndrome (HPS) after common bile duct ligation (CBDL). We have recently found that lung vascular monocyte adhesion and angiogenesis in HPS involve interaction of endothelial C-X3-C motif ligand 1 (CX3CL1) with monocyte CX3C chemokine receptor 1 (CX3CR1), although whether ET-1/ETB receptor activation influences these events is unknown. Our aim was to define if ET-1/ETB receptor activation modulates CX3CL1/CX3CR1 signaling and lung angiogenesis in experimental HPS. A selective ETB receptor antagonist, BQ788, was given for 2 weeks to 1-week CBDL rats. ET-1 (±BQ788) was given to cultured rat pulmonary microvascular endothelial cells overexpressing ETB receptors. BQ788 treatment significantly decreased lung angiogenesis, monocyte accumulation, and CX3CL1 levels after CBDL. ET-1 treatment significantly induced CX3CL1 production in lung microvascular endothelial cells, which was blocked by inhibitors of Ca(2+) and mitogen-activated protein kinase (MEK)/ERK pathways. ET-1-induced ERK activation was Ca(2+) independent. ET-1 administration also increased endothelial tube formation in vitro, which was inhibited by BQ788 or by blocking Ca(2+) and MEK/ERK activation. CX3CR1 neutralizing antibody partially inhibited ET-1 effects on tube formation. These findings identify a novel mechanistic interaction between the ET-1/ETB receptor axis and CX3CL1/CX3CR1 in mediating pulmonary angiogenesis and vascular monocyte accumulation in experimental HPS.

MATÉRIAUX
Référence de produit
Marque
Description du produit

Sigma-Aldrich
DAPI, for nucleic acid staining
Sigma-Aldrich
Luminol, 97%
Sigma-Aldrich
Fluorescein, for fluorescence, free acid
Sigma-Aldrich
Endothelin 1, ≥97% (HPLC), powder
Sigma-Aldrich
Luminol, ≥97% (HPLC)
Fluorescein, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Human Fractalkine / CX3CL1 ELISA Kit, for serum, plasma, cell culture supernatants and urine
Sigma-Aldrich
Mouse Fractalkine / CX3CL1 ELISA Kit, for serum, plasma and cell culture supernatant
Sigma-Aldrich
Rat Fractalkine ELISA Kit, for serum, plasma and cell culture supernatant
Sigma-Aldrich
Rat Fractalkine ELISA Kit, for cell and tissue lysates

Réseaux sociaux

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

Merck

Recherche. Développement. Production

Nous sommes un des tout premiers fournisseurs du secteur mondial des Sciences de la vie proposant des solutions et des services pour la recherche, le développement et la production en biotechnologies, et le développement et la production de produits thérapeutiques pharmaceutiques.

© 2021 Merck KGaA, Darmstadt, Allemagne et/ou ses sociétés affiliées. Tous droits réservés.

La reproduction d'une quelconque partie du contenu de ce site est strictement interdite sans autorisation.